Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback